TG Therapeutics (TGTX) Following Conference Appearances Is The BRIUMVI Story Still A Bargain

TG Therapeutics (TGTX) steps into the spotlight this month with back to back appearances at the H.C. Wainwright and Cantor healthcare conferences, both featuring Chairman and CEO Michael S. Weiss.

Recent trading has been choppy for TG Therapeutics, with the share price down 1.78% over the past day and 4.84% over the week, yet still showing an 8.82% 1-month share price return and an 81.15% year to date share price gain. The 3-year total shareholder return is very large, suggesting that long term momentum remains in play even as short term sentiment cools.

Spot fresh momentum stories alongside TG Therapeutics by scanning our hand picked 39 healthcare AI stocks.

Bulls see TG Therapeutics as a profitable MS pure play coming off an 81% year to date surge, while bears flag volatility and execution risk. Which story does the current valuation lean toward next?

Most Popular Narrative: 24% Undervalued

TG Therapeutics is trading at $53.04 against a widely followed fair value estimate of about $69.71, which places a lot of weight on the BRIUMVI franchise and its potential offshoots.

The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35 to 40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth.

Demographic changes, such as the aging population and the rising prevalence of chronic diseases like multiple sclerosis, are expected to drive sustained demand for advanced therapeutics. This supports both ongoing expansion of BRIUMVI sales and future pipeline potential, positively impacting both top-line revenue and long-term earnings visibility.

See why 65 investors see TG Therapeutics as 24% undervalued.

Result: Fair Value of $69.71 (UNDERVALUED)

Still, a single product focus around BRIUMVI and rising pricing and reimbursement pressure could quickly challenge the bullish TG Therapeutics narrative if competitive trends shift.

Find out about the key risks to this TG Therapeutics narrative.

Next Steps

Mixed signals around TG Therapeutics can be confusing. Move quickly, review the core numbers for yourself, and weigh both upside and downside using 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond TG Therapeutics?

If TG Therapeutics has your attention, do not stop there. Broaden your watchlist with a few focused stock ideas that match different risk and return preferences.

• Target potential mispricing opportunities by scanning our hand picked 34 high quality undervalued stocks.
• Strengthen your income stream by reviewing a curated set of dependable high yield payers in the 6 dividend fortresses.
• Reduce portfolio stress by focusing on businesses with robust financial footing through the 11 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com